Kyowa Hakko Kirin

Feb 26, 2020

Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference

Dec 13, 2019

Opting for Optimus - Cognizin® Citicoline Featured in New Drinkable Nootropic Supplement

Nov 01, 2019

Kyowa Hakko USA Celebrates 50 Years of Innovation at Supply Side West

Jun 26, 2019

Fotivda (tivozanib; AVEO Oncology/EUSA Pharma/Kyowa Hakko Kirin) Overview 2019: An Oral Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1), VEGFR-2, & VEGFR-3

Jun 03, 2019

Kyowa Kirin Presents Post-Hoc Analysis of Pivotal Trial for Poteligeo® (mogamulizumab-kpkc)

Nov 05, 2018

MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan

Aug 08, 2018

Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome

Mar 07, 2018

Aevi Genomic Medicine Expands Collaboration with Kyowa Hakko Kirin

Nov 28, 2017

Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan

Oct 27, 2017

IDO Inhibitors Pipeline Analysis 2017 - Key Players are Pfizer, Bristol-Myers Squibb & Kyowa Hakko Kirin